Skip to content
ClearheadLab
Explore

A calm evidence note

Medications That Cause Brain Fog: The Common Culprits

Anticholinergics, benzodiazepines, opioids, and sedating antihistamines can cloud thinking. The honest evidence on which drugs do it — and why not to just stop.

Written with care by Nadia BrooksUpdated

If your thinking has felt slow, hazy, or effortful and you take a regular medication, it is worth asking whether the two are connected — because for several well-studied drug classes, the answer is genuinely yes. Medication is one of the most common reversible causes of brain fog, and it is also one of the most overlooked, because people tend to blame age, stress, or sleep before they look at the bottle in the cabinet. This article walks through the drug classes with the clearest evidence for clouding cognition, separates the strong signals from the weak ones, and is blunt about the single most important rule: this is information to take to your prescriber, not a license to stop a medication on your own. Stopping some of these drugs abruptly is more dangerous than the fog.

Before anything else, the honest framing. "Brain fog" is a symptom, not a diagnosis, and medication is only one of many possible drivers — sleep debt, thyroid problems, nutrient deficiencies, post-viral illness, and mood conditions all produce the same hazy presentation, which we map in what actually causes brain fog. So the goal here is not to convince you a drug is the cause; it is to help you recognize when a medication could be contributing, so you can raise it with the person who prescribed it.

The drug classes to review

Bring this list to your prescriber — don't stop anything on your own

  • Anticholinergics (diphenhydramine, oxybutynin, amitriptyline) — strongest signal; block acetylcholine, and heavy long-term use is linked to dementia risk in cohort studies.
  • Sedating first-generation antihistamines (Benadryl) — cross into the brain; impair attention and even driving. A non-sedating second-generation swap is the usual fix.
  • Benzodiazepines & Z-drugs (alprazolam, lorazepam, zolpidem) — impair memory during use; some deficits persist after stopping. Never stop abruptly — taper only under supervision.
  • Opioids (oxycodone, tramadol, morphine) — dose-dependent clouding, but untreated pain also impairs thinking; balance is a prescriber conversation.
  • Statins — the honest exception: large randomized trials show no average cognitive harm; most complaints are nocebo. Don't quit a heart-protective drug — ask about a switch.

Anticholinergics: the strongest and most under-recognized signal

If there is one drug category to know about, it is the anticholinergics. These are drugs that block acetylcholine, a neurotransmitter central to attention and memory — and the list is much longer than most people realize. It includes older sedating antihistamines (diphenhydramine, the active ingredient in Benadryl and many "PM" sleep aids), bladder/overactive-bladder drugs (oxybutynin), tricyclic antidepressants (amitriptyline), some muscle relaxants, and certain drugs for nausea and vertigo. Many are available over the counter, which is exactly why their cognitive cost flies under the radar.

The evidence here is unusually strong for a brain-fog topic. Geriatric prescribing guidance — the American Geriatrics Society Beers Criteria — explicitly lists strongly anticholinergic drugs as potentially inappropriate in older adults precisely because of their effects on cognition1. Beyond short-term fog, large cohort studies have linked cumulative anticholinergic exposure to a higher risk of dementia: a prospective study found higher long-term use of strong anticholinergics associated with incident dementia2, and two large nested case-control studies — one in JAMA Internal Medicine and one in the BMJ — independently found an association between heavy anticholinergic use and later dementia diagnosis34. These are observational findings, so they show association rather than proof of cause, and most people taking an occasional dose are not in the heavy-use category the studies flag. But the acute effect on attention is real and immediate, and in older or hospitalized patients a high anticholinergic burden is a recognized trigger for confusion and delirium5. The practical takeaway: if you are foggy and take one or more anticholinergic drugs, that is a high-value thing to review with your prescriber — often a less anticholinergic alternative exists.

Sedating antihistamines: the over-the-counter trap

First-generation antihistamines deserve their own mention because they are so widely used and so easy to underestimate. Diphenhydramine (Benadryl) and similar older agents cross into the brain and are both sedating and anticholinergic, which is a double hit on clear thinking. The evidence is hard to wave away: in a randomized, placebo-controlled driving-simulator trial, diphenhydramine impaired driving performance — and notably did so more than alcohol at the legal limit, while the non-sedating antihistamine fexofenadine did not6. A 2026 review of antihistamines in primary care similarly concluded that the sedating first-generation agents impair cognition and daytime functioning in a way the newer non-sedating ones largely do not7. The honest, actionable version: if you reach for diphenhydramine for allergies or sleep and feel foggy, a switch to a non-sedating second-generation antihistamine (cetirizine, loratadine, fexofenadine) is the obvious conversation — we unpack that swap in detail in does Benadryl cause brain fog?.

Benzodiazepines and Z-drugs: real, and not only while you're on them

Benzodiazepines (alprazolam, lorazepam, diazepam, clonazepam) and the related "Z-drug" sleep aids work by enhancing GABA, the brain's main inhibitory signal — which is exactly why they calm anxiety and induce sleep, and also why they slow cognition. The effect on memory and processing during use is well established. More striking is what meta-analyses of long-term users have found: chronic benzodiazepine use is associated with impairment across multiple cognitive domains8, and a companion meta-analysis found that some of those deficits persist even after people withdraw from the drug, improving only partially9. That is a sobering finding, but it comes with a critical safety caveat that overrides everything: benzodiazepines must never be stopped abruptly. Sudden withdrawal can cause severe rebound anxiety, insomnia, and — at the dangerous end — seizures. Any change has to be a slow, supervised taper directed by your prescriber. This is the clearest example of why "don't just stop" is not a disclaimer but the central message.

Opioids: dose-dependent clouding

Opioid painkillers (oxycodone, hydrocodone, morphine, tramadol) act on the central nervous system, and sedation and mental clouding are recognized effects, especially during initiation and dose increases. A systematic review and meta-analysis of people on chronic opioids for non-cancer pain found measurable deficits in cognitive performance compared with controls10. The picture is genuinely two-sided, though: untreated severe pain itself impairs concentration, so for some patients adequate pain control can improve mental clarity rather than worsen it. That tension — pain versus the drug used to treat it — is exactly why opioid fog is a conversation for your prescriber, who can weigh dose, alternatives, and your pain control together, rather than a reason to cut a dose yourself.

Strength of the link to cognitive impairment

  • Anticholinergics → fog, confusion, dementia-risk associationStrong evidence

    Beers Criteria, plus large cohort and case-control studies in heavy users.

  • Sedating first-gen antihistamines → impaired cognitionStrong evidence

    Diphenhydramine impaired driving more than alcohol in a placebo-controlled trial.

  • Benzodiazepines → memory/processing impairmentStrong evidence

    Meta-analyses show deficits during use that only partly recover after withdrawal.

  • Chronic opioids → cognitive deficitsModerate evidence

    Meta-analysis in non-cancer pain; untreated pain also impairs thinking.

  • Statins → cognitive decline (on average)No evidence

    Randomized trials show no harm; most complaints reflect nocebo, not the drug.

Judged on human evidence. The honest surprise is at the bottom: statins, the drug people most often blame, do not on average impair cognition.

Statins: the honest outlier — mostly a worry, rarely a cause

Statins (atorvastatin, simvastatin, rosuvastatin) belong on any list of "drugs people blame for fog," but here the evidence pushes in the reassuring direction, and being honest means saying so. The large randomized trials and a systematic review of randomized controlled trials found that statins do not, on average, cause cognitive decline11, and a dedicated cognitive-function study within a major cardiovascular trial found no harm to memory or thinking even with very aggressive cholesterol lowering12. Where statins do cause trouble is more often a nocebo effect — symptoms that appear when people know they are taking a statin but vanish under blinding. In the ASCOT-LLA trial, certain adverse symptoms were reported more on statin therapy only when patients knew they were taking it, not in the blinded phase13. None of that erases the rare individual: genuine, reversible statin-associated cognitive complaints do occur in a small number of people and resolve on stopping. But the population evidence is clear enough that the right move is never to quietly quit a statin — these drugs prevent heart attacks and strokes — but to raise the concern with your doctor, who can trial a switch or a blinded re-challenge.

What to actually do about it

The thread running through every class above is the same: medication-related fog is one of the few brain-fog causes that is genuinely reversible — but the reversal has to be done safely. The wrong response is to stop a drug on your own; for benzodiazepines, opioids, and several others, abrupt discontinuation is more dangerous than the fog itself. The right response is to make a list. Write down everything you take, including over-the-counter sleep aids and allergy pills, note when the fog started relative to any new or increased medication, and bring that to your prescriber or pharmacist. They can spot anticholinergic burden you would never recognize, identify a clean swap (sedating to non-sedating antihistamine, for instance), or design a safe taper. Pair that with the cause-first playbook in how to clear brain fog, and if anxiety is part of why you are on a sedating drug, our overview of anxiety and brain fog may help you and your clinician find the underlying lever. For where this fits in the bigger picture of cognitive energy, see the best cognitive-energy hub.

The bottom line

Several common drug classes can genuinely cloud thinking: anticholinergics carry the strongest signal — from acute attention loss to an association with long-term dementia risk in heavy users12345; sedating first-generation antihistamines like diphenhydramine impair cognition and even driving more than alcohol67; benzodiazepines impair memory during use and the deficits can partly persist after withdrawal89; and chronic opioids are linked to measurable cognitive deficits10. Statins are the honest exception — large randomized evidence shows no average cognitive harm, with most complaints reflecting nocebo rather than the drug111213. Medication fog is reversible, which makes it worth catching — but the path is a list and a conversation with your prescriber, never stopping a drug on your own.

A few gentle questions

Which medications are most likely to cause brain fog?

Anticholinergic drugs carry the strongest signal — these block acetylcholine and include older sedating antihistamines like diphenhydramine (Benadryl), bladder drugs such as oxybutynin, and tricyclic antidepressants like amitriptyline. Benzodiazepines and Z-drug sleep aids, opioid painkillers, and sedating first-generation antihistamines also cloud thinking. Statins are the notable exception: large trials show no average cognitive harm.

Can I just stop a medication that's fogging my brain?

No — and this is the most important point. Several of these drugs, especially benzodiazepines and opioids, can be dangerous to stop abruptly, causing rebound anxiety, withdrawal, or even seizures. The right move is to make a list of everything you take (including over-the-counter sleep and allergy aids) and review it with your prescriber or pharmacist, who can identify the culprit and design a safe switch or taper.

Do statins cause memory problems?

On average, no. Systematic reviews of randomized trials and a dedicated cognitive study within a major cardiovascular trial found statins do not cause cognitive decline. Most reported complaints appear to be a nocebo effect — symptoms that show up when people know they're on a statin but not under blinding. A small number of people do have genuine, reversible complaints, but the answer is to discuss a switch with your doctor, not to quietly quit a drug that prevents heart attacks and strokes.

Is Benadryl bad for your brain?

Diphenhydramine (Benadryl) is sedating and strongly anticholinergic, and it measurably impairs attention — in one placebo-controlled trial it impaired driving more than alcohol at the legal limit. Occasional use isn't a crisis, but if you take it regularly for allergies or sleep and feel foggy, switching to a non-sedating second-generation antihistamine (cetirizine, loratadine, fexofenadine) is the obvious step to discuss with your clinician.

Where this comes from

  1. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015). American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.. Journal of the American Geriatrics Society. https://pubmed.ncbi.nlm.nih.gov/26446832/
  2. Gray SL, Anderson ML, Dublin S, et al. (2015). Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.. JAMA Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/25621434/
  3. Coupland CAC, Hill T, Dening T, et al. (2019). Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study.. JAMA Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/31233095/
  4. Richardson K, Fox C, Maidment I, et al. (2018). Anticholinergic drugs and risk of dementia: case-control study.. BMJ. https://pubmed.ncbi.nlm.nih.gov/29695481/
  5. Yamada Y, et al. (2026). Anticholinergic burden on admission assessed by the Japanese Anticholinergic Risk Scale and incident in-hospital delirium in older adults: A multicenter prospective cohort study.. Archives of Gerontology and Geriatrics. https://pubmed.ncbi.nlm.nih.gov/42060954/
  6. Weiler JM, Bloomfield JR, Woodworth GG, et al. (2000). Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator.. Annals of Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/10691585/
  7. Jaradat O, et al. (2026). Impact of Antihistamines on Sleep, Cognition, and Daily Functioning: Evidence From Primary and Community Care.. Journal of Primary Care & Community Health. https://pubmed.ncbi.nlm.nih.gov/42011952/
  8. Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004). Cognitive effects of long-term benzodiazepine use: a meta-analysis.. CNS Drugs. https://pubmed.ncbi.nlm.nih.gov/14731058/
  9. Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004). Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis.. Archives of Clinical Neuropsychology. https://pubmed.ncbi.nlm.nih.gov/15033227/
  10. Akhurst J, Lovell M, Peacock A, Bruno R (2021). A Systematic Review and Meta-Analysis of Cognitive Performance among People with Chronic Use of Opioids for Chronic Non-Cancer Pain.. Pain Medicine. https://pubmed.ncbi.nlm.nih.gov/33502504/
  11. Ott BR, Daiello LA, Dahabreh IJ, et al. (2015). Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials.. Journal of General Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/25575908/
  12. Giugliano RP, Mach F, Zavitz K, et al. (2017). Cognitive Function in a Randomized Trial of Evolocumab.. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/28813214/
  13. Gupta A, Thompson D, Whitehouse A, et al. (2017). Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).. The Lancet. https://pubmed.ncbi.nlm.nih.gov/28476288/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Read on, gently